Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31488686 | 1.00 | ABL1 (0.46) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL9803735 | 0.87 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL20633178 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL5953796 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL5953793 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL14389424 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL3451324 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL24695854 | 0.85 | ALB (0.63) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL10379562 | 0.85 | ABL1 (0.46) | ABL1RIN1ALBLMNAALDH1A1 | |
| SCHEMBL396634 | 0.85 | ALB (0.63) | ABL1RIN1ALBLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-4968788-A | DRUG DELIVERY, ANTITUMOR AGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-11-06 | — | — | US | claimed |
| WO-1990008155-A1 | BIOLOGICALLY REVERSIBLE PHOSPHATE AND PHOSPHONATE PROTECTIVE GROUPS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1990-07-26 | — | — | WO | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2021102367-A1 | ENGINEERED DNA FOR MOLECULAR ELECTRONICS | UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-3053585-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-5306618-A | Using xanthene dye reporter labeled DNA fragments | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-04-26 | — | — | US | disclosed |
| US-5242796-A | Fluorescent xanthene dye | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| US-5151507-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5102785-A | Cleaving to produce DNA fragment which are then end labeled with reporter, again cleaved to produce short fragment, separatiion; analysis | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| US-5047519-A | Alkynylamino-nucleotides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0309969-A2 | Method of gene mapping | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ABL1 1427/4885RIN1 1545/4885ALB 4137/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | ABL1 387/4885RIN1 4425/4885ALB 2637/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ABL1 1427/4885RIN1 1545/4885ALB 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.